You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 20, 2024

Investigational Drug Information for Ceralasertib


✉ Email this page to a colleague

« Back to Dashboard


What is the development status for investigational drug Ceralasertib?

Ceralasertib is an investigational drug.

There have been 21 clinical trials for Ceralasertib. The most recent clinical trial was a Phase 1 trial, which was initiated on September 15th 2022.

The most common disease conditions in clinical trials are Neoplasms, Breast Neoplasms, and Lung Neoplasms. The leading clinical trial sponsors are AstraZeneca, National Cancer Institute (NCI), and Parexel.

There are five US patents protecting this investigational drug and forty-two international patents.

Recent Clinical Trials for Ceralasertib
TitleSponsorPhase
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChAstraZenecaPhase 2
Ceralasertib Followed by Durvalumab and Nab-paclitaxel Combination in mTNBC PatientsAstraZenecaPhase 2
Ceralasertib Followed by Durvalumab and Nab-paclitaxel Combination in mTNBC PatientsIFOM, The FIRC Institute of Molecular OncologyPhase 2

See all Ceralasertib clinical trials

Clinical Trial Summary for Ceralasertib

Top disease conditions for Ceralasertib
Top clinical trial sponsors for Ceralasertib

See all Ceralasertib clinical trials

US Patents for Ceralasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ceralasertib ⤷  Sign Up Chemical compounds Astrazeneca AB (Sodertalje, SE) ⤷  Sign Up
Ceralasertib ⤷  Sign Up Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Sign Up
Ceralasertib ⤷  Sign Up Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Sign Up
Ceralasertib ⤷  Sign Up Chemical compounds AstraZeneca AB (Sodertalje, SE) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ceralasertib

Drugname Country Document Number Estimated Expiration Related US Patent
Ceralasertib Argentina AR081859 2030-06-11 ⤷  Sign Up
Ceralasertib Australia AU2011263491 2030-06-11 ⤷  Sign Up
Ceralasertib Brazil BR112012031561 2030-06-11 ⤷  Sign Up
Ceralasertib Canada CA2800203 2030-06-11 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.